Ramoplanin

Oscient Pharmaceuticals is developing Ramoplanin for the treatment of Clostridium difficile-associated disease (CDAD). Ramoplanin has Fast-Track status from the FDA and the Company has received a Special Protocol Assessment from the FDA for the Phase III clinical trial.